BACHEM N -B-

BANB SIX Swiss Exchange Healthcare & Biotech Switzerland
66.90 Fr.
2.06 %

Bachem is a Swiss company specializing in the production of peptides and chemical products for the pharmaceutical and biotechnology industries.

Performance & Momentum

6 Months 25.87 %
1 Year 22.53 %
3 Years 23.48 %
5 Years 32.85 %

Strategic Analysis

Bachem occupies a specialized industrial niche in peptide synthesis and pharmaceutical chemistry, serving laboratories and biotechnology players. Its positioning is based on high technical expertise, critical production capabilities, and long-term relationships with demanding customers, making it a strategic supplier rather than a simple contract manufacturer.

Strengths
  • Recognized specialist position in a niche segment with high technical barriers
  • Structural exposure to the growth in demand for peptides and high-quality pharmaceutical production
  • Swiss industrial base associated with a reputation for reliability and regulatory discipline
Weaknesses
  • Marked dependence on the investment and demand cycles of the biotech and pharmaceutical industry
  • Weak share-price performance over several years, reflecting high sensitivity to growth expectations and operational execution
Momentum

Momentum is clearly favorable in the short term, with a visible recovery trend following a prolonged period of underperformance. This improvement suggests renewed market confidence in the industrial positioning and operational trajectory, although the contrast with past weakness argues for caution and for confirming that the trend is sustained over time.

Similar stocks to BACHEM N -B-

Anantys Community

Be the first to share your analysis on BACHEM N -B-.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases